Our second annual ESG report highlights how our work in 2022 to industrialize drug discovery is in direct support of our vision to create a more sustainable future - not only to benefit patients, but also our employees, partners, communities, and the broader healthcare and technology innovation ecosystems.
Explore our 2023 ESG Report.
As a company driven by science, we recognize the need to act with urgency to mitigate our impact on climate change. We aim to reduce or offset GHG emissions from our operations with a goal to become net-zero by the year 2030. This includes a near-term commitment to perform a detailed measurement and analysis of our emissions, with plans to disclose Scope 1 and 2 emissions in our next ESG Report.
By 2030, we aim for roughly equal representation of female and male genders (50/50 after considering non-binary representation) for (1) the whole company and (2) Vice President and above.
We plan to direct 1% of our equity into the Recursion Foundation, our non-profit entity established in 2019. The Foundation will continue to support the communities in which Recursion is based, with a focus on helping build sustainable, diverse and equitable life science and technology hubs; expanding STEM education opportunities for diverse youth; and directing and amplifying employee volunteerism into causes aligned with the company’s mission. This includes an ongoing commitment to Altitude Lab, the life sciences incubator dedicated to supporting the next generation of diverse health care entrepreneurs, which launched in 2020 as a joint collaboration between Recursion and the University of Utah.